The SARTAN-AD trial, sponsored by Sunnybrook Health Sciences Centre, aimed to explore the potential of repurposing Telmisartan, an angiotensin receptor blocker (ARB), as a neuroprotective agent in mild to moderate Alzheimer's Disease (AD) patients. The study's termination due to recruitment challenges highlights the difficulties in enrolling participants for Alzheimer's trials, a common issue in this therapeutic area. Should the proof of concept yield positive results, it could pave the way for larger studies, potentially altering treatment paradigms for AD and expanding market opportunities for Telmisartan and Perindopril in this indication. The competitive landscape includes established AD therapies and emerging candidates, necessitating a thorough assessment of clinical efficacy and safety profiles to ensure differentiation.